Daily Cardiology Research Analysis
Analyzed 158 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today. A mechanistic study identified extracellular BRICK1 as a previously unrecognized driver of post–myocardial infarction angiogenesis, while human genetics work revealed combined loss- and gain-of-function mechanisms for RPL3L-mediated dilated cardiomyopathy. A 30-year prospective cohort in healthy women linked lipoprotein(a) thresholds to major cardiovascular outcomes, sharpening screening thresholds for long-term prevention.
Research Themes
- Post-myocardial infarction repair mechanisms and angiogenesis
- Genetic and molecular pathogenesis of cardiomyopathy
- Long-term risk stratification and screening using lipoprotein(a)
Selected Articles
1. Extracellular BRICK1 drives heart repair after myocardial infarction in mice.
This mechanistic study identifies the microprotein BRICK1 as a necessary extracellular cue for angiogenesis after myocardial infarction. BRICK1 is preferentially expressed in myeloid cells, relocates extracellularly after infarction in mice and humans, and is released during myeloid cell death, revealing an unexpected extracellular role for a WAVE-complex subunit.
Impact: Revealing an extracellular function for BRICK1 establishes a novel myeloid–endothelial axis controlling post-infarction angiogenesis, opening a therapeutic avenue targeting microproteins in cardiac repair.
Clinical Implications: While preclinical, BRICK1 could serve as a biomarker or therapeutic target to enhance angiogenesis and limit scarring after myocardial infarction. Translation will require clarifying dosing, delivery, and safety of modulating extracellular BRICK1 or its downstream pathways.
Key Findings
- BRICK1 (75-aa microprotein) is indispensable for post-infarction angiogenesis in reperfused mouse MI.
- BRICK1 is preferentially expressed in myeloid cells and relocates to the extracellular space after MI in mice and humans.
- BRICK1 is not actively secreted but is released during myeloid cell death, revealing a novel extracellular role for a WAVE complex subunit.
Methodological Strengths
- Multi-system validation across mouse MI model and human samples
- Mechanistic dissection of cellular source, localization, and release mechanism
Limitations
- Preclinical study; translational efficacy and safety in humans remain untested
- Quantitative dosing–response relationships and downstream targets were not fully defined in the abstract
Future Directions: Define downstream receptors/pathways of extracellular BRICK1, characterize pharmacology for agonism/antagonism, and test regenerative efficacy in large-animal MI models before early-phase clinical studies.
Tissue repair after myocardial infarction entails a vigorous angiogenic response that mitigates scarring and worsening of heart function. Angiogenesis in the infarct wound is guided by incompletely defined myeloid cell-endothelial cell interactions. Here, we identify the 75-amino acid microprotein BRICK1 (BRK1) as an indispensable driver of postinfarction angiogenesis in a mouse model of reperfused myocardial infarction. We show that BRK1 is preferentially expressed by myeloid cells and translocates to the extracellular space after myocardial infarction in mice and humans. As a subunit of the intracellular actin-regulatory WAVE complex, BRK1 was not previously known to function outside the cell. We find that BRK1 is not actively secreted but released during myeloid cell death. Cre-
2. Pathogenetic mechanisms of muscle-specific ribosomes in dilated cardiomyopathy.
This integrative study shows that RPL3L variants cause DCM via dual mechanisms: non-hotspot variants behave as loss-of-function permitting RPL3 compensation, while hotspot variants trigger nucleolar aggregation, disrupt rRNA processing, and prevent compensation by maintaining RPL3 repression through unproductive splicing. The work reconciles human genetics with functional models and refines variant interpretation.
Impact: Defines a unified pathogenetic model for RPL3L cardiomyopathy and establishes combined loss- and gain-of-function mechanisms, directly informing genetic screening, classification, and potential therapeutic strategies.
Clinical Implications: Improves variant pathogenicity classification for RPL3L, guiding genetic counseling and diagnosis in neonatal/infant DCM. Identifies splicing and nucleolar stress pathways as potential therapeutic targets, though clinical translation will require further preclinical validation.
Key Findings
- Hotspot RPL3L missense variants induce nucleolar protein aggregation, disrupt rRNA processing, and prevent RPL3 compensation via unproductive splicing.
- Non-hotspot variants phenocopy knockout and allow compensatory upregulation of RPL3, explaining absent phenotype in Rpl3l KO mice.
- A unified model establishes combined loss-of-function and gain-of-function mechanisms in RPL3L-associated dilated cardiomyopathy.
Methodological Strengths
- Integration of human genetics, patient tissues, and isogenic cellular models
- Mechanistic linkage from variant class to molecular pathology and phenotypic compensation
Limitations
- Rare disease with limited number of cases; generalizability needs broader cohorts
- Therapeutic modulation of implicated pathways remains to be demonstrated in vivo
Future Directions: Expand variant catalogs and functional assays across diverse populations, develop therapies targeting splicing regulation or nucleolar stress, and test rescue strategies in animal models.
The heart uses a muscle-specific ribosome in cardiomyocytes, where the ribosomal protein RPL3 is replaced by its paralog RPL3L. Rare biallelic RPL3L mutations cause fatal neonatal dilated cardiomyopathy, yet the mechanisms that link genotype to heart failure are unclear. Despite the recessive inheritance pattern in humans, Rpl3l knockout mice show no overt cardiac phenotype, probably because of compensatory RPL3 upregulation through unknown mechanisms. Here we report four additional cases and propose a unifying pathogenetic model by integrating human genetics, patient tissues and isogenic cell models. Affected individuals typically carry one of two recurrent hotspot missense variants paired with a private allele. Whereas non-hotspot variants phenocopy knockout and allow RPL3 compensation, hotspot variants induce nucleolar protein aggregation, disrupt rRNA processing and block compensation by preserving the role of RPL3L in repressing RPL3 via unproductive splicing. These findings establish combined loss-of-function and gain-of-function mechanisms for RPL3L-associated cardiomyopathy and inform genetic screening, diagnosis and therapeutic development.
3. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a).
In 27,748 healthy women followed for a median of 27.8 years, Lp(a) levels above 30 mg/dL (75th percentile) predicted higher risk of major cardiovascular events and coronary heart disease, while very high levels (≥120 mg/dL or 99th percentile) were associated with increased risks of ischemic stroke and cardiovascular death. The rs3798220 minor allele also conferred higher long-term cardiovascular risk.
Impact: Provides long-term, threshold-based risk data supporting Lp(a) screening in primary prevention and informing impending Lp(a)-lowering therapeutic strategies.
Clinical Implications: Supports Lp(a) testing in healthy women, especially to identify those above 30 mg/dL (elevated risk) and ≥120 mg/dL (very high risk) for intensified risk management and consideration of future Lp(a)-lowering therapies. Reinforces genotype-informed risk in European ancestry.
Key Findings
- Lp(a) >30 mg/dL (≈75th percentile) associated with higher 30-year risk of major cardiovascular events and coronary heart disease.
- Very high Lp(a) ≥120 mg/dL (≈99th percentile) associated with increased ischemic stroke and cardiovascular death.
- Adjusted HRs for Lp(a) ≥120 mg/dL vs <10 mg/dL: 1.54 for MACE and 1.80 for CHD; rs3798220 minor allele carriers had higher risk.
Methodological Strengths
- Large prospective cohort with median 27.8-year follow-up and adjudicated outcomes
- Threshold, percentile, and spline modeling plus genotype validation
Limitations
- Female health professionals; generalizability beyond women and non-European ancestries may be limited
- Observational design cannot prove causality; residual confounding possible
Future Directions: Evaluate Lp(a) screening strategies across diverse populations and test whether Lp(a) lowering reduces hard outcomes in primary prevention trials, leveraging these thresholds.
IMPORTANCE: Elevated lipoprotein(a) predicts high risk of cardiovascular disease among a modest proportion of healthy individuals, an issue that complicates screening guidelines. OBJECTIVE: To examine spline models, clinical thresholds, and percentiles of baseline lipoprotein(a) levels as 30-year determinants of cardiovascular risk. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted among female health professionals participating in the Women's Health Study, who were followed up prospectively from 1993 to 2023. Women without cardiovascular disease, cancer, and other major chronic illnesses had blood samples taken at baseline. All individuals with lipoprotein(a) measurements and/or of European ancestry with genotype information for the LPA rs3798220 variation were included. Data analyses were performed from January through April 2025. EXPOSURES: Continuously valued baseline lipoprotein(a), lipoprotein(a) clinical thresholds and percentiles, and LPA rs3798220 genotypes known to predict lipoprotein(a) levels among individuals of European ancestry. MAIN OUTCOMES AND MEASURES: The primary outcomes were incident major cardiovascular events, coronary heart disease, ischemic stroke, and cardiovascular death. Age- and multivariable-adjusted cause-specific Cox models were used to calculated hazard ratios for the cardiovascular outcomes. The hypothesis was formulated after collection of the data.